Healthcare Wrap Week 12: Racura rockets on trial green light as Imugene tumbles on $20m raise

• Racura Oncology (ASX:RAC) surged after approval to start its lung cancer combo trial
• Imugene (ASX:IMU) sank as a $20m equity raise reset the share count
• Several “reopen gaps” turned into extra falls when early selling didn’t stop
• FDA and US-market steps kept coming, but price reactions depended on near-term revenue or trial timing